<div>
  <p>
  </p>
  <ul>
    <li>
      <p>
        Illumina announced that the company will divest GRAIL via a third-party sale or capital markets transaction, as per the European Commission's divestiture order, to finalize the terms by the second quarter of 2024.
      </p>
    </li>
    <li>
      <p>
        On December 15, the US Fifth Circuit Court of Appeals issued its decision relating to Illumina vs. the Federal Trade Commission. Considering this opinion, Illumina has opted not to pursue further appeals of this decision.&nbsp;
      </p>
    </li>
    <li>
      <p>
        GRAIL would continue to be held separately, along with committed funding from Illumina for the company's business through the divestment process. Prior to this, Illumina had spun off GRAIL in 2016 but retained a 12% stake and subsequently reacquired the company in 2021.
      </p>
    </li>
    <li>
      <p>
        GRAIL has developed the Galleri test, the first clinically validated MCED test that reportedly can detect a signal shared by more than 50 types of cancer with 99.5% specificity and predict the cancer signal origin with high accuracy to help guide the next steps.&nbsp;
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    <a href="https://www.illumina.com/company/news-center/press-releases/press-release-details.html?newsid=fcc14ca0-2c74-4925-aabd-0ed940ee8c29">
      Press release
    </a>
  </p>
  <p>
  </p>
</div>


Precision Medicine

<div>
 <p>Illumina plans to divest GRAIL as part of a European Commission order. This will involve a sale or capital market transaction, expected to be finalised by Q2 2024. Following a US Court decision, Illumina won't pursue further legal appeals. GRAIL will continue operating separately with financial support from Illumina during the divestment process. Illumina reacquired GRAIL in 2021, having originally spun it off in 2016. GRAIL's Galleri test, a highly accurate tool capable of detecting signals from over 50 cancer types, will likely be central to future operations.</p>
</div>

Illumina to divest GRAIL after US Fifth Circuit Court of Appeals decision

PROMINENT_CATEGORY

<div>

<p>US gene sequencing firm Illumina and Chinese biotech company HaploX have teamed up to introduce a new genetic sequencing system, the NextSeq 2002Dx-CN-HAP, in Shenzhen, China. It integrates bioinformatics analysis through its DRAGEN server and offers comprehensive library amplification, sequencing, and genomic analysis. The collaboration is intended to boost scientific research, clinical applications and impact the biomedical sector in the Guangdong-Hong Kong-Macao Greater Bay Area.</p>

</div>

Illumina and HaploX partner to launch genetic sequencing system

DISRUPTOR_PRESENT

<div>
<ul>
<li><p>Genetic testing and CDx tools provider Illumina has launched a program, The Global Health Access Initiative, to provide reduced pricing on certain pathogen sequencing tools for public health in low- and middle-income countries. This will be available to qualified global health funding entities.</p></li>
<li><p>Targeted applications include drug resistance profiling in tuberculosis, whole-genome sequencing of emerging and reemerging viruses to monitor virus evolution and support outbreak response, broad respiratory pathogen detection for influenza-like illness surveillance, wastewater, and other environmental surveillance applications to track pathogens and antimicrobial resistances at the population level.</p></li>
</ul>
</div>

Illumina offers lower prices on pathogen sequencing tools for public health in low- and middle-income countries

<div>
 
 <ul>
  <li><p>Genetic testing and CDx tools providers Veracyte and Illumina have entered a collaboration to develop decentralized in-vitro diagnostic (IVD) tests.</p></li>
  <li><p>The tests will be offered via Illumina’s NextSeq 550Dx next-generation sequencing instrument.</p></li>
  <li><p>The tests will be used for diagnosing and treating specific ailments like cancerous lung nodules and early-stage breast cancer.</p></li>
 </ul>
 
</div>

Veracyte and Illumina partner to develop decentralized in-vitro diagnostic tests

Jacob Thaysen, currently the senior vice president of Agilent Technologies, has been appointed as the new CEO of gene sequencing company Illumina, effective September 25, 2023. Thaysen has a background in clinical diagnostics and has been with Agilent for ten years. The former CEO, Francis deSouza, resigned in June 2023 amidst an investor proxy battle and regulatory opposition to the acquisition of Grail. Thaysen's role will involve leading the company and dealing with the challenges related to Illumina's Grail acquisition. Charles Dadswell, the interim CEO, will return to his position as senior vice president and general counsel.

All Updates

Illumina to divest GRAIL after US Fifth Circuit Court of Appeals decision

Illumina and HaploX partner to launch genetic sequencing system

Illumina offers lower prices on pathogen sequencing tools for public health in low- and middle-income countries

Veracyte and Illumina partner to develop decentralized in-vitro diagnostic tests

Illumina appoints Jacob Thaysen as CEO

Illumina expands genomic solutions into India

Illumina beats analysts’ expectations in Q2 2023; reduces full-year guidances

Illumina and Pillar Biosciences partner to enhance personalized cancer treatment

MedGenome acquires Illumina’s NovaSeq X Plus

Illumina announces layoffs; plans to exit satellite campus in San Diego